The Effects of 5G Radiation on Skin

Last updated: February 7, 2024
Sponsor: Prof. Olivier Gaide, MD-PhD
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

5GFR2 non ionizing EMW exposure

Clinical Study ID

NCT05933954
CHUV-DD-00884-SEAWAVE-2023
  • Ages > 18
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The current 5G waves used on the daily life are ranging from 410 MHz to 7125 MHz and are called FR1. The next deployed 5G waves will be FR2, from 24.45 GHz to 52.6 GHz. Our project targets the 27.5 GHz frequency, as it will be used in both Europe and the USA. Recent studies have shown that these 5G FR2 waves enter the skin but do not penetrate deeper in the body, which is why our project focuses on the skin.

Our aim is to understand the effects of 5G waves on skin by performing a clinical trial. In this study, participants (healthy volunteers, patients with dermatoporosis, or whose skin is prone to developing cancer or who suffer from atopic dermatitis) will be exposed to carefully chosen 5G parameters and skin will be analyzed by state-of-the-art single cell RNA analysis (an unbiased and very sensitive technique ideal for studying cell behavior changes). This project will also decipher the differences between women and men, in response to 5G FR2 waves.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants will be recruited in accordance with European and Swiss standards for thefollowing groups: Healtyh volunteers or Dermatoporosis defined as a chronic skinfragility syndrome orGorlin Goltz Syndrome defined as OMIM 10940014, or FamilialCylindromatosis or SB Syndrome defined as OMIM 132700/60504114, or XPV defined as OMIM 27875014 or Atopic dermatitis defined as a chronic inflammatory skin diseasecharacterised by eczematous skin lesions and intense pruritus
  • Able to give informed consent as documented by signature,
  • Adults, from 18 to 80 yo, according to groups

Exclusion

Exclusion Criteria:

  • Recent intense exposure to sun (defined as causing a sunburn, within the last 7 days)
  • Pregnant (excluded with a pregnancy test) or lactating women,
  • Patients taking anti-coagulants
  • Clinically significant concomitant diseases (cutaneous exam by the specialist),
  • Active enrolment in another clinical trial,
  • Participants incapable of judgment or participants under tutelage.

Study Design

Total Participants: 42
Treatment Group(s): 1
Primary Treatment: 5GFR2 non ionizing EMW exposure
Phase:
Study Start date:
January 09, 2024
Estimated Completion Date:
July 01, 2025

Connect with a study center

  • CHUV

    Lausanne, Vaud 1011
    Switzerland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.